Pharmacogenomics and Toxicogenomics of Bioactive Peptides: Special Focus on Therapeutic Peptides

Bioactive peptides and peptide-based therapeutics have emerged as a rapidly expanding class of pharmacological agents used to treat metabolic diseases, cancer, infectious diseases, and cardiovascular disorders. Advances in peptide engineering, structural optimization, and delivery technologies have accelerated the clinical translation of peptide drugs. Concurrently, pharmacogenomics and toxicogenomics are transforming precision medicine by enabling individualized prediction of drug efficacy, adverse reactions, and toxicological responses. Pharmacogenomics examines how genetic variability influences pharmacokinetics and pharmacodynamics, whereas toxicogenomics integrates transcriptomics, proteomics, metabolomics, and systems biology to characterize molecular toxicity pathways. This study comprehensively reviews the intersection of pharmacogenomics and toxicogenomics in bioactive peptides, with emphasis on therapeutic peptides and peptide drugs. We also discuss genomic determinants of peptide drug response, toxicogenomic biomarkers, omics-based safety evaluation, regulatory perspectives, computational approaches, and future directions for precision peptide therapeutics.

Authors

Institutions

Publication Details

Journal
Advances in Pharmacology and Therapeutics Journal
Published
2026-11-17
DOI
https://doi.org/10.18502/aptj.v6i2.23225
Primary Topic
Pharmacogenetics and Drug Metabolism
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pharmacogenomics and Toxicogenomics of Bioactive Peptides: Special Focus on Therapeutic Peptides

Adel Ghorani‐Azam, Hadi Abbasian, Naser Shokrzadeh, Samaneh Sepahi
3 links
Advances in Pharmacology and Therapeutics Journal
Pharmacogenetics and Drug Metabolism
article

Pharmacogenomics and Toxicogenomics of Bioactive Peptides: Special Focus on Therapeutic Peptides

Adel Ghorani‐Azam, Hadi Abbasian, Naser Shokrzadeh, Samaneh Sepahi
article en

Abstract

Bioactive peptides and peptide-based therapeutics have emerged as a rapidly expanding class of pharmacological agents used to treat metabolic diseases, cancer, infectious diseases, and cardiovascular disorders. Advances in peptide engineering, structural optimization, and delivery technologies have accelerated the clinical translation of peptide drugs. Concurrently, pharmacogenomics and toxicogenomics are transforming precision medicine by enabling individualized prediction of drug efficacy, adverse reactions, and toxicological responses. Pharmacogenomics examines how genetic variability influences pharmacokinetics and pharmacodynamics, whereas toxicogenomics integrates transcriptomics, proteomics, metabolomics, and systems biology to characterize molecular toxicity pathways. This study comprehensively reviews the intersection of pharmacogenomics and toxicogenomics in bioactive peptides, with emphasis on therapeutic peptides and peptide drugs. We also discuss genomic determinants of peptide drug response, toxicogenomic biomarkers, omics-based safety evaluation, regulatory perspectives, computational approaches, and future directions for precision peptide therapeutics.

Advances in Pharmacology and Therapeutics Journal
Urmia University (IR), Ministry of Health and Medical Education (IR), Urmia University of Medical Sciences (IR)
Good health and well-being
Pharmacogenetics and Drug Metabolism
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon